Efficacy of mefloquine in the treatment of skin leishmaniasis in an endemic area of Leishmania (Viannia) braziliensis

• Autor(es):

  Laguna-Torres, Victor Alberto (Faculdade de Medicina do Triângulo Mineiro);

  Silva, Carlos A.C. (Universidade Federal da Bahia);

  Correia, Dalmo (Faculdade de Medicina do Triângulo Mineiro);

  Carvalho, Edgard M. (Universidade de Brasília);

  Magalhães, Albino V. (Universidade de Brasília);

  Macedo, Vanize de Oliveira (Universidade de Brasília).

• Fonte:

  Revista da Sociedade Brasileira de Medicina Tropical; volume 32, número 5, páginas 529-532. Outubro 1999.

• Assuntos:

  Mefloquine;

  Tegumentary leishmaniasis;

  Glucantime.

• Resumo:

  The aim of this study was to evaluate the efficacy of mefloquine in the treatment of skin leishmaniasis in patients infected with Leishmania (Viannia) braziliensis at an endemic region. Mefloquine is an oral drug effective against malaria with a prolonged half-life, less toxicity and easier administration than pentavalent antimonials. At Corte de Pedra in the Southern litoral of Bahia State, two randomized groups of ten patients with leishmaniasis were treated. The first group was treated with oral mefloquine, 250mg per day in a single dose for six days and repeated three weeks later. The second group received meglumine antimoniate (Glucantime®), 20mg/kg daily administered intravenously for 20 days. Only one patient in the group treated with mefloquine showed evidence of clinical success. During treatment, one patient with four lesions developed a new lesion. The other three patients with clinical leismaniasis did not show evidence of clinical success after nine weeks of treatment. The group treated with Glucantime® showed evident clinical improvement of the skin lesions.

• Acesse o texto completo (Português)